TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35546402
Drug: 4-hydroxysalicylanilide (HDS)
Normalized name: Atuss HD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-hydroxysalicylanilide (HDS) in combination with melphalan and bortezomib
Study: 35546414
Drug: Ramosetron ODT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron ODT 0.1 mg administered after discharge on postoperative days 1 and 2
Study: 35546414
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (metoclopramide 10 mg administered only when nausea/vomiting occurred)
Study: 35546555
Drug: Anakinra (100-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (100-300 mg administered intravenously for 15 days)
Study: 35546669
Drug: Eribulin (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin (1.4 mg/m² initial dose)
Study: 35548446
Drug: Reduced bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced bolus bivalirudin (80% of normal dose)
Study: 35549674
Drug: Spartalizumab in
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Spartalizumab in combination with FLOT regimen (fluorouracil, leucovorin, oxaliplatin, and docetaxel)
Study: 35550037
Drug: COVID-19 vaccines
Normalized name: Covid-19 vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 vaccines (various Emergency Use Authorization or licensed formulations)
Study: 37993355
Drug: Ebola vaccine
Normalized name: ebola vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebola vaccine trial
Study: 35551072
Drug: Surpass flow
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surpass flow diverter treatment
Study: 35551087
Drug: Therapeutic plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic plasma exchange (TPE) on days 5-7, in addition to standard of care radiotherapy and immunotherapy.
Study: 35551087
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care radiotherapy and immunotherapy.
Study: 35551366
Drug: SARS-CoV-2 mRNA
Normalized name: SARS-CoV-2 mRNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 mRNA vaccines (mRNA-1273, BNT162b2)
Study: 35552391
Drug: FET-PET-based SIB
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: FET-PET-based SIB intensity-modulated radiotherapy (78 Gy total dose, 2.6 Gy per fraction)
Study: 35552827
Drug: Tinzaparin (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin (fixed dose, 10,000 Anti-Xa IU, OD)
Study: 35558645
Drug: Opioid prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid prescriptions at discharge
Study: 35558645
Drug: Alcohol and
Normalized name: Polyvinyl alcohol and povidone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol and other drugs (AOD) status
Study: 35559387
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis combined with mechanical thrombectomy (Group A)
Study: 35559387
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment and intravenous thrombolysis (Group B)
Study: 35566502
Drug: Age, time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age, time since COVID-19, hospitalization, dizziness, joint pain, pre-existing cardiopulmonary disease, use of beta blockers
Study: 37393513
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of nusinersen
Study: 35567345
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg dose of nusinersen
Study: 35567422
Drug: Risdiplam, orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risdiplam, orally once daily for a median duration of 4.8 months (range, 0.3-9.2 months)
Study: 35567560
Drug: sLOX-1 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: sLOX-1 levels in ACS patients undergoing serial intracoronary imaging and statin therapy
Study: 35567881
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning (ML) analysis applied to 3D maxillofacial shapes
Study: 35567881
Drug: 3D geometric
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D geometric morphometrics combined with ML
Study: 35567914
Drug: Palbociclib plus
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib plus an aromatase inhibitor (P+AI)
Study: 35568047
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of bone marrow-derived allogeneic mesenchymal stromal cells (MSCs)
Study: 35568909
Drug: Precision cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precision cancer drugs through IMPRESS-Norway
Study: 35570280
Drug: SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitors (SGLT2-I)
Study: 35570280
Drug: Other oral
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other oral anti-diabetic agents (non-SGLT2-I)
Study: 35570383
Drug: Ticagrelor (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (90 mg) combined with aspirin
Study: 35570983
Drug: VIS649 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIS649 0.5 mg/kg
Study: 35570983
Drug: VIS649 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIS649 2.0 mg/kg
Study: 35570983
Drug: VIS649 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIS649 6.0 mg/kg
Study: 35570983
Drug: VIS649 12.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIS649 12.0 mg/kg
Study: 35570983
Drug: VIS649 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIS649 6.0 mg/kg + vaccine
Study: 35571928
Drug: IQP-AE-103 (proprietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: IQP-AE-103 (proprietary combination of dehydrated okra powder and inulin)
Study: 35572740
Drug: PVP-I nasal
Normalized name: PVP-I
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PVP-I nasal spray (NS) at diluted concentrations of 0.5%
Study: 35572740
Drug: PVP-I nasal
Normalized name: PVP-I
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PVP-I nasal spray (NS) at diluted concentrations of 0.6%
Study: 35573002
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for chronic-active antibody-mediated rejection (caABMR)
Study: 35574368
Drug: Neoadjuvant Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant Chemotherapy (NACT)
Study: 35574426
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg twice daily (b.d.)
Study: 35574426
Drug: Tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 10 mg twice daily (b.d.)
Study: 35574956
Drug: Kidney injury
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kidney injury molecule-1 and interleukin-18
Study: 35575974
Drug: DTaP-IPV vaccine
Normalized name: DTaP-IPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV vaccine (TETRAXIM™)
Study: 35576349
Drug: Ulipristal Acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ulipristal Acetate with adjunct Misoprostol
Study: 35576508
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy plus nivolumab (paclitaxel 200 mg/m2)
Study: 35576508
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy plus nivolumab
Study: 35576529
Drug: Mitapivat (AG-348)
Normalized name: Mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitapivat (AG-348) 50 mg BID
Study: 35576960
Drug: Navitoclax plus
Normalized name: navitoclax
DrugBank: Navitoclax (DB12340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navitoclax plus ruxolitinib (navitoclax orally administered at 50 mg per day, escalated weekly to a maximum of 300 mg per day)
Study: 35577503
Drug: Emactuzumab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emactuzumab (1000 mg) + Atezolizumab (1200 mg)
Study: 35577814
Drug: Flexible insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flexible insulin therapy (FIT) with heart rate sensors and automated closed insulin loop
Study: 35578270
Drug: Aggressive interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aggressive interventions (hospital death, anti-cancer treatment, more than 14 days in hospital, more than one hospital admission, more than one emergency room visit, at least one ICU admission)
Study: 35578615
Drug: Granola with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granola with low beta-glucan (0.8 g)
Study: 35578615
Drug: Granola with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granola with medium beta-glucan (3.2 g)
Study: 35578615
Drug: Granola with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granola with high beta-glucan (6.6 g)
Study: 35578615
Drug: Control (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (200 ml low-fat milk)
Study: 35578807
Drug: Chronic metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic metformin treatment with aerobic training (EXER+MET)
Study: 35578807
Drug: Aerobic training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerobic training without metformin (EXER)
Study: 35578807
Drug: Chronic metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic metformin treatment
Study: 35579486
Drug: Medication iatrogenic
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication iatrogenic assessment using Trivalle score
Study: 35579486
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of potentially inappropriate medications
Study: 35579486
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of benzodiazepine prescriptions
Study: 35579486
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of anticholinergic prescriptions
Study: 35579731
Drug: KX2-391 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: KX2-391 120 mg
Study: 35579731
Drug: KX2-391 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: KX2-391 160 mg
Study: 35579731
Drug: KX2-391 140
Approvals — FDA: no, EMA: no, PMDA: no
Description: KX2-391 140 mg
Study: 35579840
Drug: Medium Dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium Dose (MD) of MVC-COV1901
Study: 35579840
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose (HD) of MVC-COV1901
Study: 35579840
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose (LD) of MVC-COV1901
Study: 35579840
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of MVC-COV1901
Study: 35579840
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of MVC-COV1901
Study: 35579862
Drug: Naxitamab in
Normalized name: naxitamab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naxitamab in combination with granulocyte-macrophage colony-stimulating factor
Study: 35580913
Drug: Prereferral rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prereferral rectal artesunate (RAS)
Study: 35581627
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg t-PA with 5 mg DNase administered over 24 h
Study: 35585554
Drug: Moderate protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate protein intake (0.8-1.2 g/kg)
Study: 35585554
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein intake (< 0.8 g/kg)
Study: 35585554
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein intake (> 1.2 g/kg)
Study: 35585867
Drug: Transcranial Electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial Electromagnetic Treatment (TEMT)
Study: 35587408
Drug: Adolescent Identity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adolescent Identity Treatment (AIT)
Study: 35587487
Drug: Everolimus (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (4.5 mg/m2 daily for 7 days)
Study: 35587536
Drug: Prophylactic-dose subcutaneous
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic-dose subcutaneous enoxaparin (40 mg once daily) for 6 months after 3 months of therapeutic-dose LMWH.
Study: 35587650
Drug: Relugolix (by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relugolix (by mouth once daily)
Study: 35588104
Drug: Glabellar onabotulinumtoxinA
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Glabellar onabotulinumtoxinA injections
Study: 35588274
Drug: Modified fluid
Normalized name: modified fluid gelatin
DrugBank: Succinylated gelatin (DB16568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified fluid gelatin 4% in a balanced electrolyte solution
Study: 35588274
Drug: Albumin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin (50 g L)
Study: 35588317
Drug: Idursulfase-IT 10
Normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Idursulfase-IT 10 mg or 30 mg administered monthly via IT drug delivery device or lumbar puncture
Study: 35588317
Drug: Idursulfase-IT treatment
Normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Idursulfase-IT treatment
Study: 35588692
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg Q3W for 35 cycles (2 years)
Study: 35588752
Drug: Tazemetostat 800
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tazemetostat 800 mg once on day 1 and then twice daily from day 2 onwards (part 1); Tazemetostat 800 mg twice daily starting on day 1 of cycle 1 (part 2)
Study: 35589164
Drug: Previous statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous statin therapy
Study: 35589352
Drug: Dolutegravir/lamivudine dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir/lamivudine dual antiretroviral therapy
Study: 35589352
Drug: Other dual-drug
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other dual-drug and three-drug combinations
Study: 35589542
Drug: BNT162b2 COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 COVID-19 vaccine, 2 doses
Study: 35590143
Drug: JAK1 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: JAK1 inhibitor itacitinib
Study: 35591977
Drug: IV etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV etoposide 100 mg/m²
Study: 35592513
Drug: Achieved 25(OH)D
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Achieved 25(OH)D concentrations ≥40 ng/mL
Study: 35594123
Drug: Topiramate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (100 mg/day, 200 mg/day, 400 mg/day)
Study: 35595617
Drug: SN-5 questionnaire
Normalized name: sn-3-GPC
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SN-5 questionnaire after 4-week treatment
Study: 35595730
Drug: Pirtobrutinib (LOXO-305),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirtobrutinib (LOXO-305), a reversible inhibitor of Bruton's tyrosine kinase (BTK)
Study: 35597904
Drug: Volasertib (250-350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volasertib (250-350 mg on D1 and D15)
Study: 35597904
Drug: Volasertib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volasertib monotherapy
Study: 35598186
Drug: vemurafenib/cobimetinib administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: vemurafenib/cobimetinib administered via feeding tube
Study: 35598441
Drug: SJ733 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: SJ733 (300 mg daily for 3 days)
Study: 35598441
Drug: SJ733 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: SJ733 (600 mg daily for 3 days)
Study: 35598441
Drug: SJ733 (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: SJ733 (75 mg single dose) + cobicistat (150 mg single dose)
Study: 35598441
Drug: SJ733 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: SJ733 (300 mg single dose) + cobicistat (150 mg single dose)
Study: 35598441
Drug: SJ733 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: SJ733 (600 mg single dose) + cobicistat (150 mg single dose)
Study: 35598441
Drug: SJ733 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: SJ733 (600 mg single dose) ± cobicistat
Study: 35600486
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg Q2W plus statin therapy (atorvastatin 20 mg/day or rosuvastatin 10 mg/day)
Study: 35601412
Drug: HMO supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMO supplement
Study: 35602004
Drug: Nanocovax vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanocovax vaccine (25 mcg, 50 mcg, and 75 mcg doses with 0.5 mg aluminium hydroxide adjuvant)
Study: 35602004
Drug: Placebo (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.5 mg aluminium hydroxide adjuvant only)
Study: 35602475
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clindamycin and low dose TMP/SMX (CT group)
Study: 35602475
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of TMP/SMX (T group)
Study: 35603165
Drug: EGFRvIII-directed CAR
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFRvIII-directed CAR T cell therapy
Study: 35603278
Drug: Bispecific LV20.19
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bispecific LV20.19 CAR T cell therapy
Study: 35603905
Drug: Neoadjuvant/induction platinum-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant/induction platinum-based combination chemotherapy (NAIC)
Study: 35603905
Drug: Combination immune
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination immune checkpoint inhibition (cICI)
Study: 35604212
Drug: Alternative dolutegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative dolutegravir dosing regimens
Study: 35605011
Drug: Plasma antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma antibodies from SFV-infected individuals
Study: 35605481
Drug: Cenobamate (12.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate (12.5, 25, 50, 100, 150, 200 mg/day, target dose 200 mg/day, with further increases to 400 mg/day by 50 mg/day increments every other week)
Study: 35606646
Drug: Potentially inappropriate
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially inappropriate medication prescribing (PIP) detected by a computer algorithm
Study: 35606731
Drug: ClinTouch DAWN-P
Approvals — FDA: no, EMA: no, PMDA: no
Description: ClinTouch DAWN-P app for daily EPDS assessments
Study: 35607994
Drug: Aspirin treatment
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin treatment in 2015
Study: 35608376
Drug: 4-week exercise
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week exercise and nutrition prehabilitation program (blood flow restriction exercise and sports nutrition supplement)
Study: 35608822
Drug: Selinexor (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor (40 mg on days 1, 8, 15) and Ibrutinib (420 mg daily)
Study: 35608822
Drug: Selinexor and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor and Ibrutinib combination
Study: 35608877
Drug: Time to
Normalized name: Overtime Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time to imaging, antibiotic therapy, and surgery
Study: 35609913
Drug: Remdesivir (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remdesivir (200 mg IV on day 0, followed by 100 mg IV daily for 10 days) plus standard treatment
Study: 35609913
Drug: Remdesivir plus
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remdesivir plus standard treatment
Study: 35610084
Drug: 150-300 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150-300 g fish/week
Study: 35610144
Drug: Thyroid hormones
Normalized name: Thyroid hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormones (TSH, fT3, fT4) as continuous variables
Study: 35610367
Drug: Resection/local ablative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resection/local ablative therapy (LAT)
Study: 35610367
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy only
Study: 35611499
Drug: Durvalumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab monotherapy (10 mg/kg every 2 weeks)
Study: 35611499
Drug: Durvalumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab plus tremelimumab (durvalumab 20 mg/kg every 4 weeks plus tremelimumab 1 mg/kg for 4 doses, followed by durvalumab 20 mg/kg Q4W)
Study: 35613775
Drug: Blood tests
Normalized name: Blood tests, auxiliary products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood tests on Oral Glucose Tolerance Test (OGTT) and haemoglobin A1C (HbA1c)